Blum Kenneth, Kazmi Shan, Modestino Edward J, Downs Bill William, Bagchi Debasis, Baron David, McLaughlin Thomas, Green Richard, Jalali Rehan, Thanos Panayotis K, Elman Igor, Badgaiyan Rajendra D, Bowirrat Abdalla, Gold Mark S
College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.
Institute of Psychology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary.
J Pers Med. 2021 Mar 16;11(3):212. doi: 10.3390/jpm11030212.
This article describes a unique therapeutic precision intervention, a formulation of enkephalinase inhibitors, enkephalin, and dopamine-releasing neuronutrients, to induce dopamine homeostasis for detoxification and treatment of individuals genetically predisposed to developing reward deficiency syndrome (RDS). The formulations are based on the results of the addiction risk severity (GARS) test. Based on both neurogenetic and epigenetic evidence, the test evaluates the presence of reward genes and risk alleles. Existing evidence demonstrates that the novel genetic risk testing system can successfully stratify the potential for developing opioid use disorder (OUD) related risks or before initiating opioid analgesic therapy and RDS risk for people in recovery. In the case of opioid use disorders, long-term maintenance agonist treatments like methadone and buprenorphine may create RDS, or RDS may have been in existence, but not recognized. The test will also assess the potential for benefit from medication-assisted treatment with dopamine augmentation. RDS methodology holds a strong promise for reducing the burden of addictive disorders for individuals, their families, and society as a whole by guiding the restoration of dopamine homeostasisthrough anti-reward allostatic neuroadaptations. WC 175.
本文描述了一种独特的精准治疗干预方法，即一种脑啡肽酶抑制剂、脑啡肽和释放多巴胺的神经营养物质的配方，用于诱导多巴胺稳态，以对具有发展为奖赏缺乏综合征（RDS）遗传易感性的个体进行解毒和治疗。这些配方基于成瘾风险严重程度（GARS）测试的结果。基于神经遗传学和表观遗传学证据，该测试评估奖赏基因和风险等位基因的存在情况。现有证据表明，这种新型基因风险检测系统能够在启动阿片类镇痛治疗之前，成功地对发展为阿片类药物使用障碍（OUD）相关风险或康复者的RDS风险进行分层。对于阿片类药物使用障碍，像美沙酮和丁丙诺啡这样的长期维持激动剂治疗可能会引发RDS，或者RDS可能已经存在但未被识别。该测试还将评估多巴胺增强药物辅助治疗的获益潜力。RDS方法通过引导通过抗奖赏适应性神经适应恢复多巴胺稳态，有望为减轻个体、其家庭以及整个社会的成瘾性疾病负担带来巨大希望。WC 175。
